Aarti Pharma Labs Quarterly Results for Trading Insights
In Sept 2025, Aarti Pharma Labs (AARTIPHARM) reported revenue ₹418 Cr and net profit ₹28 Cr — revenue -9.7% YoY. For annual financials, live price and key ratios, visit Aarti Pharma Labs share price chart.
AARTIPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Aarti Pharma Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with AARTIPHARM fair price to assess whether the stock is under or overvalued.
- Revenue of ₹418 Cr in Sept 2025 (-25.6% vs Mar 2025, -9.7% vs Sept 2024)
- Net Profit of ₹28 Cr in Sept 2025 (-68.2% vs Mar 2025, -49.1% vs Sept 2024)
- EBITDA of ₹74 Cr in Sept 2025 (-48.6% vs Mar 2025)
- Operating Margin of 18.0% in Sept 2025 (-8.0pp vs Mar 2025)
- Earnings Per Share of ₹3.08 in Sept 2025 (-68.4% vs Mar 2025)
Aarti Pharma Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AARTIPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 418 | 562 | 388 | 437 | 463 | -25.6% | -9.7% |
| Net Profit (₹ Cr) | 28 | 88 | 50 | 48 | 55 | - | - |
| EBITDA (₹ Cr) | 74 | 144 | 95 | 104 | 98 | - | - |
| EPS (₹) | 3.08 | 9.75 | 5.46 | 5.29 | 6.03 | - | - |
| Operating Margin (%) | 18.0% | 26.0% | 24.0% | 23.0% | 20.0% | - | - |
AARTIPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Aarti Pharma Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore AARTIPHARM stock price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AARTIPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Aarti Pharma Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores